Sen. Johnson Questions FDA's Drug Approval Process for Rare Diseases

Senator Ron Johnson has initiated an investigation into the FDA's drug approval process, particularly regarding treatments for rare diseases that have faced rejection.

This inquiry stems from a recent conversation with FDA Commissioner Marty Makary, where key issues surrounding the agency's handling of these treatments were discussed.

The implications of this investigation could affect the regulatory landscape for rare disease therapies, potentially altering approval pathways and impacting patient access.